Acutaas Chemicals Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹32,775 Cr
- P/E
- 84.85
- ROE
- 24.04%
- PEG
- 1.37
- Price to sales
- 22.42
- Debt to equity
- 0.02
- 52W high / low
- ₹4,004 / ₹1,602
- Sales growth (5Y)
- 31.50%
- EBITDA margin
- 37.12%
- Net profit margin
- 26.61%
- Promoter holding
- 32.66%
- Sales (last year)
- ₹1,462 Cr
Guidance scorecard · Q2 FY27 call
What Acutaas Chemicals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
20–40%- The company targets a 25% revenue growth for the full financial year FY '27.
- Battery chemicals business expected to ramp up to full capacity utilization (4,000 MT) by FY '29, indicating strong volume growth.
- Semiconductor business (Indichem plant) to start contributing revenues from FY '28 and expected to reach full capacity within 3-4 years.
- Pharma Intermediates, including CDMO business, expected to grow strongly, with CDMO revenue target of INR 1,000 crores and confident to exceed it.
- Spec Chem business revenue mix to grow due to battery chemicals and new higher-margin specialty chemicals despite phasing out commodity chemicals.
2 more points from Acutaas Chemicals Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Acutaas Chemicals Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Additional capex planned for a new R&D center and land acquisition for future capacity expansion; details to be announced when finalized.
- Land acquisition is intended to support capacity expansion for the Pharma Intermediate business as existing plants (Sachin and Ankleshwar) approach full utilization by FY '28.
- Indichem plant construction is ahead of schedule, with capex completion expected by end of Q1 FY '27; revenue anticipated from next financial year.
2 more points from Acutaas Chemicals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Acutaas Chemicals Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- Battery chemical business has active long-term supply contracts for VC and FEC products, with full capacity utilization expected within 3 years.
- Third product in battery electrolytes developed, with a long-term supply contract in finalization stage; fourth product planned afterward.
- Semiconductor business (Indichem plant) is newly commissioned; product development and business development underway with expectations to ramp up revenue from next financial year.
- CDMO business in Pharma Intermediates has robust growth and multiple projects in the R&D pipeline to reduce concentration risk.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Acutaas Chemicals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingAcutaas Chemicals Ltd announcements
All announcements →- Financial resultsMajor developmentAcutaas Chemicals Limited announces Q2 and H1 FY2027 unaudited financial results
Financials of Acutaas Chemicals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Acutaas Chemicals Ltd
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 39.91% | 39.91% | 35.98% | 35.97% | 35.96% | 35.96% | 32.66% | 32.66% | 32.66% | 32.66% | 32.66% | 32.66% |
| FIIs + | 11.66% | 8.98% | 12.93% | 13.87% | 15.52% | 16.48% | 16.94% | 16.84% | 16.67% | 19.48% | 21.61% | 22.61% |
| DIIs + | 7.58% | 6.80% | 14.81% | 19.93% | 20.23% | 18.31% | 22.38% | 22.59% | 21.70% | 19.60% | 19.55% | 19.40% |
| Government + | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public + | 40.85% | 44.31% | 36.28% | 30.24% | 28.27% | 29.22% | 28.00% | 27.89% | 28.96% | 28.24% | 26.16% | 25.31% |
| No. of Shareholders | 83,344 | 95,784 | 90,987 | 93,394 | 95,756 | 1,14,060 | 1,19,890 | 1,08,664 | 1,10,363 | 1,12,939 | 1,25,569 | 1,47,026 |
Financials of Acutaas Chemicals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 172 | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 | 437 |
| Expenses + | 148 | 140 | 182 | 147 | 198 | 206 | 224 | 156 | 211 | 243 | 249 | 217 | 261 |
| Operating Profit | 25 | 27 | 43 | 30 | 49 | 69 | 85 | 51 | 95 | 151 | 184 | 113 | 176 |
| OPM % | 14% | 16% | 19% | 17% | 20% | 25% | 28% | 25% | 31% | 38% | 42% | 34% | 40% |
| Other Income + | -30 | 3 | 1 | 1 | 8 | 2 | 6 | 16 | 10 | 5 | 11 | 2 | 5 |
| Interest | 1 | 3 | 2 | 4 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 4 | 5 | 6 | 7 | 6 | 7 | 8 | 8 | 10 | 10 | 10 | 13 |
| Profit before tax | -10 | 24 | 37 | 20 | 50 | 63 | 83 | 58 | 96 | 145 | 184 | 104 | 167 |
| Tax % | 71% | 25% | 31% | 26% | 25% | 28% | 24% | 24% | 25% | 27% | 27% | 28% | 26% |
| Net Profit + | -17 | 18 | 26 | 15 | 38 | 45 | 63 | 44 | 72 | 106 | 134 | 75 | 123 |
| EPS in Rs | -2.55 | 2.27 | 3.41 | 1.71 | 4.56 | 5.49 | 7.63 | 5.41 | 8.82 | 13.19 | 16.09 | 9.07 | 15.29 |
Financials of Acutaas Chemicals Ltd
Profit & Loss
Annual income statement trend
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 160 | 188 | 239 | 240 | 341 | 520 | 617 | 717 | 1,007 | 1,339 | 1,593 |
| Expenses + | 137 | 157 | 196 | 198 | 260 | 415 | 493 | 589 | 775 | 859 | 969 |
| Operating Profit | 23 | 31 | 42 | 42 | 80 | 105 | 123 | 128 | 232 | 480 | 623 |
| OPM % | 14% | 16% | 18% | 17% | 24% | 20% | 20% | 18% | 23% | 36% | 39% |
| Other Income + | 0 | 3 | 0 | 2 | 1 | 3 | 4 | -25 | 17 | 42 | 23 |
| Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 6 | 6 | 3 | 4 |
| Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 16 | 27 | 36 | 42 |
| Profit before tax | 19 | 28 | 35 | 35 | 72 | 91 | 112 | 82 | 216 | 483 | 600 |
| Tax % | 35% | 35% | 34% | 21% | 25% | 21% | 26% | 41% | 26% | 26% | |
| Net Profit + | 12 | 18 | 23 | 27 | 54 | 72 | 83 | 49 | 160 | 356 | 439 |
| EPS in Rs | 1.91 | 2.94 | 3.70 | 4.36 | 8.57 | 9.87 | 11.43 | 5.80 | 19.38 | 43.51 | 53.64 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 15% | 13% | 26% | 8% | 6% |
Financials of Acutaas Chemicals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 10 | 10 | 32 | 36 | 36 | 37 | 41 | 41 | 41 |
| Reserves | 37 | 56 | 72 | 101 | 135 | 486 | 558 | 637 | 1,269 | 1,613 | 1,817 |
| Borrowings + | 27 | 44 | 54 | 59 | 137 | 1 | 4 | 217 | 13 | 36 | 15 |
| Other Liabilities + | 43 | 54 | 77 | 61 | 110 | 136 | 169 | 205 | 227 | 295 | 348 |
| Total Liabilities | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 | 1,984 | 2,221 |
| Fixed Assets + | 28 | 32 | 79 | 85 | 186 | 205 | 259 | 427 | 570 | 745 | 1,115 |
| CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 | 125 | 130 | 332 | 67 |
| Investments | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 0 | 0 | 0 | 0 |
| Other Assets + | 68 | 91 | 131 | 133 | 225 | 450 | 477 | 543 | 848 | 907 | 1,039 |
| Total Assets | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 | 1,984 | 2,221 |
Financials of Acutaas Chemicals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 29 | 8 | 15 | 27 | 28 | -12 | 66 | 125 | 118 | 292 |
| Cash from Investing Activity + | -19 | -25 | -21 | -24 | -101 | -121 | -33 | -365 | -224 | -266 |
| Cash from Financing Activity + | -7 | 15 | 6 | 0 | 72 | 140 | -12 | 239 | 261 | 4 |
| Net Cash Flow | 3 | -2 | -0 | 3 | -1 | 8 | 20 | -1 | 156 | 30 |
| Free Cash Flow | 10 | -16 | -7 | 6 | -77 | -46 | -31 | -155 | -76 | -36 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 153% | 53% | 68% | 85% | 52% | 10% | 73% | 116% | 71% | 84% |
Financials of Acutaas Chemicals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 97 | 116 | 86 | 129 | 115 | 136 | 105 | 105 | 99 |
| Inventory Days | 76 | 89 | 95 | 148 | 123 | 150 | 131 | 139 | 119 | 149 |
| Days Payable | 148 | 154 | 168 | 146 | 172 | 158 | 157 | 119 | 103 | 99 |
| Cash Conversion Cycle | 11 | 31 | 43 | 88 | 80 | 107 | 111 | 125 | 121 | 149 |
| Working Capital Days | 46 | 64 | 28 | 34 | 51 | 141 | 139 | 80 | 123 | 116 |
| ROCE % | 38% | 34% | 27% | 33% | 24% | 21% | 16% | 20% | 32% |
Guidance history
How Acutaas Chemicals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 20–40% | Flat | Planned | — | — |
| Q4 FY26 call → | 20–40% | Flat | Planned | — | — |
| Q3 FY26 call → | 20–40% | Up 2%+ | Planned | — | Rising |
| Q2 FY26 call → | 20–40% | Flat | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
93 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +135.0% | 96% |
| Last 6 months | +54.3% | 90% |
| Last 3 months | +28.9% | 92% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Acutaas Chemicals Ltd: 0.4 × 96 + 0.4 × 90 + 0.2 × 92 = 93.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Acutaas Chemicals Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL